Back to School: How biopharma can reboot drug development. Access exclusive analysis here
A good day for biotech issues pushed the BioCentury 100 up 4.3 percent to 2998.26, with advancing issues outpacing
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury